Comparative Pharmacology
Head-to-head clinical analysis: ERYPED versus ERYTHRO STATIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYPED versus ERYTHRO STATIN.
ERYPED vs ERYTHRO-STATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin acts by binding to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step. It is a macrolide antibiotic.
Erythro-statin is a combination of erythromycin, a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, and a statin (HMG-CoA reductase inhibitor) that inhibits cholesterol synthesis. Synergistic effects on inflammation and atherosclerosis are hypothesized.
250–500 mg orally every 6 hours or 500–1000 mg intravenously every 6 hours; maximum 4 g/day.
200 mg intravenously once daily.
None Documented
None Documented
2-4 hours (prolonged to 4-6 hours in neonates and patients with hepatic impairment); requires q6h dosing for most indications.
2.0-3.5 hours in adults with normal renal function. Extended to 5-8 hours in patients with severe renal impairment (CrCl <30 mL/min).
Primarily hepatic (biliary excretion of unchanged drug and metabolites); approximately 5% renal excretion as unchanged drug.
Approximately 70-80% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion. About 20-30% is eliminated unchanged in feces via biliary secretion.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic